Spinout Active LTD

Company profile

Ferryx Limited

Gut Health Supplements For A Calmer Digestive System | Ferrocalm

Improve your digestive system with Ferrocalm, a trusted gut health supplement for a calmer and healthier you.

CRN
12193693
Founded
2019
Age
6

Overview

Browse spinouts
Legal name
FERRYX LIMITED
Region
South West England
Registered address
FUTURE SPACE UWE NORTH GATE
FILTON ROAD
STOKE GIFFORD
BRISTOL
ENGLAND
BS34 8RB
Insolvency history
No

Latest accounts

Financial period: 1 Oct 2023 to 30 Sep 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
-£300,242
Employees
2

Company events

Reference milestones and recent Companies House filing stream events.

6 events
01 Jan
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Jun
2026

Accounts due

Accounts Due

Next accounts due date

19 Jun
2026

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzUyNzM3NjkwOGFkaXF6a2N4

Published 19 Jun 2026 18:51

18 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Sep
2024

Accounts filed

Accounts

Last accounts made up date

06 Sep
2019

Incorporated

Inception

Company registered at Companies House

Spinout profile

4 entries

Company description

Ferryx develops pharmaceuticals, designed to treat inflammatory conditions.

Ferryx are developing a safe and effective probiotic to prevent or treat gastrointestinal inflammation. Unlike many conventional probiotics, our proprietary strain thrives in the inflamed gut and exerts anti-inflammatory effects.

Project impact

Too early to record notable impacts.

FERRYX LIMITED
2019

Public funding

2 awards
First funded
2022
Funded years
2022, 2024
Age at first award
3 years

Projects

2024 Collaborative R&D Lead participant

Evaluation of the interactions of a novel live biotherapeutic product for the treatment of gut inflammation with the GI tract in an in vitro model

1 May 2024 to 30 Apr 2025

Awarded
£92,436
Total cost £92,436

There is a lack of satisfactory treatments for inflammatory bowel disease (IBD), an excruciating, debilitating condition which affects 1 in 123 people in the UK (\\\>0.5 million) and 6.8 million worldwide. Currently available treatments have significant negative side effects, affecting quality of life of patients and reducing compliance, leading to exacer...

2022 Grant for R&D Lead participant

Assessment of a multi strain live biotic feed additive in reducing environmental impact and improving productivity in chicken production

1 Nov 2022 to 31 Jan 2023

Awarded
£45,884
Total cost £45,884

The production of chicken to produce meat is responsible for the production of the greenhouse gas methane and the environmental pollutant ammonia. These are produced by the birds as they are reared and also by the litter that they live on. The bacteria that produce these chemicals live in the chicken's intestine. Any intervention that would reduce these b...

Product types

Collaborative R&D Grant for R&D